BioAge Labs vs Evommune
BIOA and EVMN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIOA and EVMN compare
BioAge Labs and Evommune are about the same size, with market caps of $259M and $291M.
BioAge Labs grew revenue faster over the last twelve months (45.3% versus −100% for Evommune).
BioAge Labs scores higher on the StockData Score (8 against 7 for Evommune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIOA | EVMN |
|---|---|---|
| Size and price | ||
| Market cap | $259M | $291M |
| Share price | $5.65 | $8.02 |
| Change, 1 year | −27.8% | −58.8% |
| Beta (5Y) | 1.80 | 0.96 |
| Employees | 62 | 48 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 30.2× | – |
| P/B | 0.7× (better) | 1.2× |
| FCF yield | −39.7% | −31.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 45.3% (better) | −100% |
| Profitability | ||
| Operating margin | −1402% | – |
| Net margin | −1254% | – |
| FCF margin | −1198% | – |
| Return on equity | −34.6% (better) | −331% |
| Return on invested capital | −325% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −913.2× | – |
| Current ratio | 15.51 (better) | 8.52 |
| Altman Z-score | 5.60 (better) | 4.17 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.2% | 95.4% |
| Held by insiders | 21.9% | 51.6% |
| Insider net buying, 12 months | −$7.8M | −$2.1M (better) |
| Short interest, % of float | 10.4% | 19.3% |
Go deeper
- BIOA stock overview
- BIOA income statement
- BIOA valuation and score
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.